Skip to main content
. 2024 Jun 6;15:4847. doi: 10.1038/s41467-024-49224-x

Fig. 5. PNPLA3 depletion reduces VLDL particle size and TG content as well as impairs hepatic TG secretion upon LXR agonism.

Fig. 5

a Representative time course of hepatic TG secretion in mice upon administration of Poloxomer-407. Priorly, 10-week-old WT mice were fed COWD and treated with control (n = 6) or PNPLA3 ASO (n = 7) and administered T09 for 3 weeks. b Data from (a) represented as secretion rate per hour. c–f Shotgun lipidomics was performed on plasma samples from the 3 h timepoint in (a) (n = 4/group). Individual FA species composition of TG presented as absolute FA abundance (c) and as percentage of the total FA pool (d). Individual FA species composition of PC presented as absolute FA abundance (e) and as percentage of the total FA pool (f). Plasma samples pooled from control or PNPLA3 ASO mice administered T09 were fractionated by FPLC (4-5 mice/group). Lipoprotein fractions were measured for the content of TG (g) and cholesterol (h). i Plasma samples were immunoblotted for ApoB-100 and ApoB-48. j EM analysis of lipoprotein particles from control and PNPLA3 ASO mice +T09. k Quantification of VLDL particle size distribution of (J). Scale bar = 200 nm. Data presented as mean ± SD *p < 0.05, **p < 0.01, two-sided t test. Specific p values: (a) 1 h, p = 0.214; 2 h, p = 0.00661; 3 h, p = 0.00544; 4 h, p = 0.00643. (b) p = 0.00212. (c) 16:0, p = 0.00923; 18:0, p = 0.0452; 16:1, p = 0.00309; 18:1, p = 0.00587; 18:2, p = 0.00125. e 16:0, p = 0.00718; 18:0, p = 0.0344; 18:1, p = 0.0109; 18:2, p = 0.00194; 20:3, p = 0.0456; 20:4, p = 0.00966; 22:6, p = 0.00454.